The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Explains the Greatest Challenge in Treating Patients With MDS and AML

Christopher R. Cogle, MD
Published Online:4:00 PM, Mon February 11, 2019


Christopher R. Cogle, MD, a professor of medicine at the University of Florida, discusses the greatest challenge in treating patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Both MDS and AML are very heterogenous diseases where a patient has multiple MDS or AML clones, Cogle says. In his research, he found that there were hundreds of genomic abnormalities in each patient.

At this same time, MDS and AML were also being treated with single targeted therapies. This didn’t sit right with Cogle, as the agents in this trials were only matching 1 gene mutation out of the hundreds. He and his colleagues mapped all of the mutations in MDS and AML in order to better understand these diseases.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.